NEFL and Alzheimer disease: The FTD diagnostic panel (containing 9 out of the 14 proteins) confirmed discrimination of FTD from controls with high accuracy in all validation cohorts (clinical cohort 1: AUC = 0.96, 95% CI: 0.92-1; clinical cohort 2: AUC = 0.96, 95% CI: 0.92-1; FTLD/AD autopsy cohort: AUC = 0.98, 95% CI: 0.95-1; Fig. 4B) and was similar to CSF NfL (clinical cohort 1: AUC = 0.95, 95% CI: 0.87-1; Fig. 4C).